<DOC>
	<DOCNO>NCT00044213</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness ethylene diamine tetra-acetic ( EDTA ) chelation therapy individual coronary artery disease .</brief_summary>
	<brief_title>Trial Assess Chelation Therapy ( TACT )</brief_title>
	<detailed_description>EDTA chelation therapy involve repeat administration synthetic amino acid reduce atherosclerotic plaque mineral deposit throughout cardiovascular system . Participants randomly assign receive 40 infusion either standard chelation solution placebo . The primary endpoint trial composite cause mortality , myocardial infarction , stroke , coronary revascularization , hospitalization angina . The result TACT provide either significant positive result informative null result upon rational clinical decision-making health policy base .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Edetic Acid</mesh_term>
	<mesh_term>Pentetic Acid</mesh_term>
	<criteria>Inclusion Criteria Participants : Heart attack least 6 week prior study start Exclusion Criteria Participants : Serum creatinie level great 2.0 mg/dL Platelet count le 100,000/ÂµL Blood pressure great 160/100 Chelation therapy within 5 year prior study start History allergic reaction EDTA therapy 's component Coronary carotid revascularization procedure within 6 month prior study start schedule revascularization Cigarette smoking within 3 month prior study start Childbearing potential History liver disease Active heart failure heart failure hospitalization within 6 month . Diagnoses additional medical condition could otherwise limit patient survival Inability tolerate 500mL infusion weekly .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>